A5049610479- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Breast Cancer Treatment Studies
- Cervical Cancer and HPV Research
- Global Cancer Incidence and Screening
- Colorectal and Anal Carcinomas
- Advanced Breast Cancer Therapies
- Cancer Risks and Factors
- COVID-19 and healthcare impacts
- Economic and Financial Impacts of Cancer
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Women's cancer prevention and management
- Sperm and Testicular Function
- Genital Health and Disease
- CRISPR and Genetic Engineering
- Nausea and vomiting management
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Genomic variations and chromosomal abnormalities
- Peptidase Inhibition and Analysis
- Uterine Myomas and Treatments
- PARP inhibition in cancer therapy
- Lymphoma Diagnosis and Treatment
- Ovarian function and disorders
- Health Literacy and Information Accessibility
Clinics Hospital of Ribeirão Preto
2022-2025
Centro de Pesquisas Oncológicas
2025
Fleury S.A. (Brazil)
2022-2023
Hospital de Câncer de Barretos
2019-2022
Instituto de Neurociências e Comportamento
2016-2017
Cliniques Universitaires Saint-Luc
2012
UCLouvain
2012
Breast cancer (BC) in young women is uncommon and tends to present with more aggressive characteristics. To better understand characterize this scenario Brazil through real-world data, we performed a subanalysis of AMAZONA III study (ClinicalTrials.gov identifier: NCT02663973).The (GBECAM 0115) prospective registry that included 2,950 newly diagnosed invasive BC from January 2016 until March 2018 at 22 sites. Valid data were obtained 2,888 patients regarding age diagnosis complete baseline...
Background Along with BRCA mutation status, homologous recombination deficiency (HRD) testing is a prognostic and predictive biomarker for poly-ADP-ribose polymerase (PARP) inhibitor therapy indication in high-grade epithelial ovarian, fallopian tube, or peritoneal cancer. Approximately 50% of serous ovarian cancers exhibit HRD, even the absence germline somatic 1/2 loss-of-function mutations. In this scenario, access to validated diagnostic HRD test can optimize treatment selection increase...
Low rates of germline genetic testing (GGT) for breast cancer (BC) have been reported globally, with limited data from low- and middle-income countries (LMICs). In this study, we used real-world to assess the GGT rate BC in an LMIC identified barriers its use. We analyzed 2,974 newly diagnosed patients AMAZONA III largest Brazilian multicenter, prospective cohort. were determined entire cohort high-risk hereditary group (HR), defined by National Comprehensive Cancer Network criteria, between...
PURPOSE A nationwide lockdown was enforced in Brazil starting March 2020 because of the COVID-19 pandemic when cancer screening activities were reduced. In this study, we evaluated impact on breast (BC) diagnosis. METHODS We extracted data from medical records patients age older than 18 years who diagnosed with BC and started treatment or follow-up private oncology institutions between 2018 2021. The primary objective to compare stage distribution during (2020-2021) a historical prepandemic...
Background Endometrial cancer presents well-defined risk factors: myometrial invasion, histological subtype, tumor grade, lymphovascular space invasion (LVSI). Some low and intermediate-risk endometrioid endometrial patients exhibited unexpected outcomes. This study aimed to investigate other clinical-pathological factors that might influence the recurrence rates of diagnosed with cancer. Methods A case-control from a cohort retrospective 196 at single institution 2009 2014 was conducted....
Abstract Objective To evaluate the difference between early and delayed removal of indwelling urinary catheter after radical hysterectomy (RH) or trachelectomy (RT). Methods An ambispective study was conducted in early‐stage cervical cancer patients who underwent RH RT. Delayed occurred on a postoperative day (POD) 7 retrospective group (January 2012‐November 2013), POD 1 prospective (May 2014‐June 2017). The postvoid residual (PVR) test performed both groups. Results Our sample included 47...
OBJETIVO: Avaliar a taxa de resposta patológica completa atingida pelas pacientes com diagnóstico câncer mama localmente avançado submetidas à quimioterapia neoadjuvante baseada no esquema doxorrubicina/ciclofosfamida seguido paclitaxel. MÉTODOS: Coorte retrospectiva admitidas Hospital Câncer Barretos entre 2006 e 2008 ao protocolo paclitaxel (4 ciclos doxorrubicina 60mg/m² ciclofosfamida 600mg/m² cada 21 dias; 4 175mg/m² dias). As seguintes variáveis foram avaliadas: idade, menopausa,...
To describe a series of cases ovarian Sertoli-Leydig cell tumors (SLCTs). Retrospective review 12 SLCT treated at the Hospital do Câncer de Barretos, state São Paulo, Brazil, between October 2009 and August 2017. The median age patients was 31 years old (15-71 old). A total 9 (75.0%) presented symptoms: 8 (66.7%) with abdominal pain, 5 (41.7%) enlargement, 2 (16.7%) virilizing signs, abnormal uterine bleeding, 1 (8.3%) dyspareunia, weight loss. preoperative lactate dehydrogenase (LDH) 504.5...
The molecular profile of endometrial cancer has become an important tool in determining patient prognosis and their optimal adjuvant treatment. In addition to Cancer Genome Atlas (TCGA), simpler tools have been developed, such as the Proactive Molecular Risk Classifier for Endometrial (ProMisE). We attempted determine a genetic signature build recurrence risk score patients diagnosed with low- intermediate-risk cancer.A case-control study was conducted. eligible were women between January...
Endometrial cancer is of increasing concern in several countries, including Brazil, part because an ageing population, declines fertility, and the prevalence obesity. Although endometrial tumors had lagged behind other types terms treatment improvements, molecular characterization these paving way for novel therapies expansion therapeutic arsenal. We aimed to help medical oncologists who manage patients with recurrent or metastatic Brazilian healthcare setting.The panel, composed 20...
To develop and validate a new multimedia instrument to measure health-related quality of life (HRQOL) in Portuguese-speaking patients with cancer. A mixed-methods study conducted large Brazilian Cancer Hospital. The was developed along the following sequential phases: identification HRQOL issues through qualitative content analysis individual interviews, evaluation most important items according patients, review literature, by an expert committee, pretesting. In sequence, exploratory factor...
Zanon, Jeferson R MD, MSc; Simioni, Elisa B MD; Barbin, Flávia F Pedrão, Priscila G Andrade, Carlos E M C de Diocésio A P PhD; Bilibio, João Fregnani, José Humberto T dos Reis, Ricardo PhD Author Information
Purpose Molecular classification of endometrial cancer (EC) has emerged as a key approach to individualize therapy and define prognostic outcomes. This study aimed implement the traditional ProMisE in Brazilian population, compared with molecular setting biomarkers, evaluate its impact on patients’ prognosis. Patient methods A prospective cohort 114 patients primary EC treated at Barretos Cancer Hospital (BCH) between October 2020 December 2022 was conducted. Pathology diagnosis, staging,...
Brazil is a middle-income country with inequalities in its healthcare system. The disparities between public and private services affect the diagnosis treatment of patients breast cancer. aim this study to assess whether disease-free survival (DFS) overall (OS) are different specialized centers.A retrospective cohort 1,545 cancer diagnosed from 2003 2011 at Barretos Cancer Hospital-BCH (public group, N = 1,408) InORP Oncoclinicas (private 137) was conducted. A 1:1 propensity score matching...